This week. The tweeter referenced a WS trading desk. Link is on IV site
I know this is hard for you Obamanites to accept. O's economic policy is a disaster, foreign policy a wreck and domestically I think Obamacare is the best description.
Don't know but the country would be much better off if our leaders followed JFK's views imo.
What's your phone number Mr. Investor? I'll give you a call...
DO for your country....
know how the game is played. beat down the pps and pick it up on the cheap just in time for the big run...
It is a new look at data from multiple studies. It is published by THE JOURNAL for CVD. Read it your self.
The study did an excellent job pointing why 'fish oils' don't provide the clinical results seen with Vascepa. It's all about metabolism to active drugs.
Warrington, PA — December 04, 2012 — Discovery Laboratories, Inc. (NASDAQ:
DSCO) today announced the release of data from a new pharmacoeconomic analysis
demonstrating that the previously-reported reduced rate of reintubation in preterm
infants treated with SURFAXIN® may also result in an average potential hospital cost
savings of $389,247 per 100 treated infants by reducing the frequency of
bronchopulmonary dysplasia (BPD) when compared with reintubation rates of infants
treated with the current global market leading surfactants, Curosurf® and Survanta®.
The analysis was presented at the 2012 Hot Topics in Neonatology Annual Meeting
held December 2-4 in Washington D.C. Hot Topics in Neonatology is an internationally
recognized medical meeting dedicated to advancing the practice of neonatology.
“It has been previously reported that infants who require reintubation are three times
more likely to develop BPD compared with those infants who are not reintubated,”
said Dr. Russell G. Clayton, Senior Vice President, Research & Development, of
Discovery Labs. “This new pharmacoeconomic analysis suggests that the selection of a
specific surfactant could significantly impact hospital costs by potentially reducing the
risk of developing BPD associated with reintubation. These data may be important to
physicians and pharmacists as they consider SURFAXIN for inclusion on hospital
Warrington, PA — September 6, 2012— Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced the publication of SURFAXIN® (lucinactant) preclinical data in Pediatric Research. Using a well-established preterm lamb model of respiratory distress syndrome (RDS), study investigators concluded that early intervention with SURFAXIN may mitigate progression of pulmonary pathophysiological consequences of RDS when compared with the animal-derived surfactants Curosurf® and Survanta®. The newly-published data can be found in the September 2012 issue of Pediatric Research, a peer-reviewed medical journal widely read by academic neonatologists and other neonatal health care professionals.
According to study findings, subjects receiving surfactant replacement therapy (SRT) using SURFAXIN had improved sustained oxygenation and lower ventilatory pressure requirements (p
DATA driven. Clinical data for SURFAXIN is very strong and gets stronger every year. Its an easy case to make.
According to a source, an internal memo circulated at Eisai indicates that the company is adding 114 new representatives and 100 contract reps. Training for the added force is reported to be starting this week. The memo cites that by December of 2013 the sales force concentrating on the anti-obesity drug Belviq will be over 400. This is up from the 200 dedicated representatives that have been making calls on doctors since the launch in June.
not giving my shares up
they do nothing but screw things up